Legend Biotech Gains Access to MaxCyte’s Cell Engineering Tech with New License Agreement
China’s Legend Biotech Corporation (NASDAQ: LEGN) has entered into a strategic platform license (SPL) agreement...
MaxCyte
Lion TCR Partners with MaxCyte to Develop mRNA-Based TCR-T Therapies for Solid Tumors and Viral Diseases
Lion TCR, a Singapore-based clinical-stage biotechnology company with backing from Chinese investors, has entered into...